Ontology highlight
ABSTRACT:
SUBMITTER: Arai S
PROVIDER: S-EPMC5650298 | biostudies-other | 2017 Sep
REPOSITORIES: biostudies-other
Arai Sachiko S Kita Kenji K Tanimoto Azusa A Takeuchi Shinji S Fukuda Koji K Sato Hiroshi H Yano Seiji S
Oncotarget 20170516 43
Rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) accounts for approximately 1-2% of all NSCLCs. To date, RET fusions that involve at least six fusion partners in NSCLC, such as KIF5B, CCDC6, NCOA4, TRIM33, CLIP1, and ERC1, have been identified. Recent clinical trials for RET fusion-positive NSCLC using vandetanib or cabozantinib demonstrated positive clinical response and considerable differential activities for RET inhibitors among fusion partners. Alectin ...[more]